HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Vimentin expression does not assist in predicting survival in ductal carcinoma of the breast.

AbstractAIMS:
To establish the value of vimentin expression in predicting survival in patients with breast cancer.
METHODS:
Five-year follow-up data were obtained for 68 patients with ductal carcinoma (NOS) of the breast in whom vimentin expression had been studied in fresh frozen and formalin-fixed, paraffin-embedded tissue. The predictive value on survival of tumour size, growth fraction (as assessed using the Ki67 monoclonal antibody), oestrogen receptor status and Bloom and Richardson grade of the primary tumour, and the presence or absence of lymph node metastases in axillary samples, were also studied.
RESULTS:
Twenty-two patients died of their disease within 5 years of diagnosis. Vimentin expression either on frozen or paraffin sections did not provide a statistically significant prediction of survival. On univariate analysis tumour grade, size and the presence of lymph node metastases provided prognostic information. Only lymph node status was of independent prognostic importance on multivariate analysis.
CONCLUSIONS:
Whilst these results confirm the value of established prognostic factors, they do not support the use of vimentin expression in either fresh or fixed tissue for the prediction of survival in ductal carcinoma (NOS) of the breast.
AuthorsM K Heatley, P Ewings, W Odling Smee, P Maxwell, P G Toner
JournalPathology (Pathology) Vol. 34 Issue 3 Pg. 230-2 (Jun 2002) ISSN: 0031-3025 [Print] England
PMID12109782 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Biomarkers, Tumor
  • Ki-67 Antigen
  • Receptors, Estrogen
  • Vimentin
Topics
  • Biomarkers, Tumor (metabolism)
  • Breast Neoplasms (metabolism, mortality, pathology)
  • Carcinoma, Ductal, Breast (metabolism, mortality, secondary)
  • Female
  • Humans
  • Immunoenzyme Techniques
  • Ki-67 Antigen (metabolism)
  • Lymph Nodes (pathology)
  • Lymphatic Metastasis
  • Middle Aged
  • Neoplasm Staging
  • Receptors, Estrogen (metabolism)
  • Survival Rate
  • Vimentin (biosynthesis)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: